Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ZTS

Zoetis

NYSE

Real-time Quotes | Nasdaq Last Sale

164.66

+1.19

+0.73%

Opening 10:35 04/14 EDT

OPEN

164.33

PREV CLOSE

163.47

HIGH

164.84

LOW

163.70

VOLUME

262.18K

TURNOVER

52 WEEK HIGH

176.64

52 WEEK LOW

121.50

MARKET CAP

78.22B

P/E (TTM)

48.11

Veterinary Drugs Market Size 2021 by Opportunities, Challenges, Risks, Influences Factors Analysis and Forecast to 2025 Research Report by Absolute Reports

Apr 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." An animal drug (also veterinary drug)...

The Express Wire · 2h ago

Veterinary Research Laboratory (Vrl) Market Size to Witness Huge Growth by 2028

Apr 14, 2021 (Market Insight Reports) -- Selbyville, Delaware According to the research report titled 'GLOBAL Veterinary Research Laboratory (Vrl) Market...

Market Insight Reports · 8h ago

Bennett Selby Investments Lp Buys Microsoft Corp, Domino's Pizza Inc, Floor & Decor ...

GuruFocus News · 16h ago

Carl P. Sherr & Co., LLC Buys iShares Core MSCI Total International Stock ETF, Zoetis Inc, ...

GuruFocus News · 18h ago

Norway Savings Bank Buys iShares MBS ETF, PIMCO Active Bond ETF, Generac Holdings Inc, Sells ...

GuruFocus News · 22h ago

Should You Be Impressed By Zoetis Inc.'s (NYSE:ZTS) ROE?

Simply Wall St. · 23h ago

FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

Zacks.com · 1d ago

Global Veterinary Diagnostics Market (2021 to 2026) - Growth, Trends, COVID-19 Impact, and Forecasts

Dublin, April 13, Apr 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostics Market - Growth, Trends,...

GlobeNewswire · 1d ago

Forecast

Actual (USD)

Estimate (USD)

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of ZTS. Analyze the recent business situations of Zoetis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZTS stock price target is 186.67 with a high estimate of 210.00 and a low estimate of 159.00.

EPS

Institutional Holdings

Institutions: 1.72K

Institutional Holdings: 459.42M

% Owned: 96.72%

Shares Outstanding: 475.02M

TypeInstitutionsShares

Increased

582

17.03M

New

168

2.28M

Decreased

435

22.18M

Sold Out

1.19M

Performance
Asset Allocation
Dividend History

No Data

Industry

Pharmaceuticals

+0.48%

Pharmaceuticals & Medical Research

+1.07%

Key Executives

Non-Executive Chairman/Independent Director

Michael McCallister

Chief Executive Officer/Director

Kristin Peck

Chief Financial Officer/Executive Vice President

Glenn David

Chief Human Resource Officer/Executive Vice President

Roxanne Lagano

Executive Vice President/General Counsel/Secretary

Heidi Chen

Executive Vice President

Catherine Knupp

Executive Vice President

Roman Trawicki

Director

Juan Alaix

Director

Antoinette Leatherberry

Independent Director

Frank D'Amelio

Independent Director

Paul Bisaro

Independent Director

Frank D'amelio

Independent Director

Sanjay Khosla

Independent Director

Gregory Norden

Independent Director

Louise Parent

Independent Director

Willie Reed

Independent Director

Linda Rhodes

Independent Director

Robert Scully

Independent Director

William Steere

Declaration Date Dividend Per Share Ex-Div Date: 02/10/2021
Dividend USD 0.25
04/20/2021; 12/09/2020
Dividend USD 0.25
01/19/2021; 10/07/2020
Dividend USD 0.2
10/20/2020; 05/20/2020
Dividend USD 0.2
07/16/2020; 02/11/2020
Dividend USD 0.2
04/16/2020; 12/11/2019
Dividend USD 0.2
01/16/2020; 10/03/2019
Dividend USD 0.164
10/21/2019; 05/15/2019
Dividend USD 0.164
07/18/2019; 02/12/2019
Dividend USD 0.164
04/17/2019; 12/12/2018
Dividend USD 0.164
01/17/2019; 10/10/2018
Dividend USD 0.126
11/19/2018; 05/15/2018
Dividend USD 0.126
07/19/2018; 02/13/2018
Dividend USD 0.126
04/19/2018; 12/11/2017
Dividend USD 0.126
01/18/2018; 10/05/2017
Dividend USD 0.105
11/08/2017; 05/22/2017
Dividend USD 0.105
06/13/2017; 02/15/2017
Dividend USD 0.105
04/04/2017; 12/07/2016
Dividend USD 0.105
01/18/2017; 10/06/2016
Dividend USD 0.095
11/01/2016; 05/13/2016
Dividend USD 0.095
06/28/2016; 02/22/2016
Dividend USD 0.095
04/05/2016; 12/18/2015
Dividend USD 0.095
01/19/2016; 10/01/2015
Dividend USD 0.083
11/03/2015; 07/21/2015
Dividend USD 0.083
08/11/2015; 02/27/2015
Dividend USD 0.083
04/07/2015; 12/17/2014
Dividend USD 0.083
01/20/2015; 10/02/2014
Dividend USD 0.072
11/03/2014; 07/31/2014
Dividend USD 0.072
08/18/2014; 03/27/2014
Dividend USD 0.072
04/24/2014; 12/19/2013
Dividend USD 0.072
01/28/2014; 09/13/2013
Dividend USD 0.065
10/30/2013; 06/21/2013
Dividend USD 0.065
07/30/2013

All
Financials
Insiders

About ZTS

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.